Global Epo Biomarkers Market: Regional Analysis
North America is expected to hold a dominant position in the epo biomarkers market over the forecast period, owing to robust healthcare infrastructure and increasing prevalence of cancer in the region. According to World Health Organization’s (WHO) 2018 report, around 609,640 deaths were recorded due to cancer and around 1.7 million new cases of cancer were diagnosed in 2018 in the U.S.
Asia Pacific is expected to witness significant growth in the epo biomarkers market, owing to presence of major companies such as 3Sbio Group, Biocon Ltd., Genscript, Intas Pharmaceuticals Ltd., Kyowa Hakko Kirin Co., Ltd., and Shandong Kexing Bioproducts Co. Ltd. Moreover, increasing prevalence of AIDS in India, China, Pakistan, and Bangladesh is also contributing to epo biomarker market growth. For instance, according to the UNAIDS Data 2018 for Asia Pacific region, in India 2.1 million people are living with HIV AIDS at the end of 2017.
Epo Biomarkers Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients